Sanderling Ventures sold $97.1M worth of shares in Endocyte Inc. in December 2018
Jan 08, 2019
Sanderling Ventures is a venture capital firm seeks investment opportunities companies located in US. The firm targets companies operating in the fields Small molecule therapeutics Biologics and vaccines Drug delivery Platform technologies Medical devices Diagnostics Digital/eHealth. The firm provides financing for seed and early stage capital requirements.
In The News
May 26, 2020 - Axios.com
Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.
In The News
MorphImmune, Inc., a Research Bridge Partners Portfolio Company, Appoints Ronald Martell as President and CEO; -- The former President and CEO of Nuvelution Pharma also served as the CEO of three public biopharmaceutical companies, including Sevion and Ne
Jun 08, 2021 - PR Newswire
MorphImmune, Inc. Appoints Ronald Martell as President and CEO; -- The former President and CEO of Nuvelution Pharma also served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX, and has overseen billions of dollars i
Jun 02, 2021 - PR Newswire
May 04, 2021 - GlobeNewswire